Henjum, Kristi
Quist-Paulsen, Else
Zetterberg, Henrik
Blennow, Kaj
Nilsson, Lars N. G.
Watne, Leiv Otto
Funding for this research was provided by:
Universitetet i Oslo
Helse Sør-Øst RHF (2013016)
Civitan Norge
Norwegian National Health Organization
Article History
Received: 7 June 2018
Accepted: 9 October 2018
First Online: 3 November 2018
Ethics approval and consent to participate
: The study was conducted in accordance with the Helsinki Declaration. Informed consent was obtained from the patients or by the closest relative if the patient were unable to give consent. The Regional Committee for Ethics in Medical and Health Research in Norway and the ethical council of the hospital approved the study (REK 2009/450 and REK 2011/2578).
: Not applicable.
: LN, KH, LOW, and EQP declare that they have no competing interests. HZ has served at advisory boards for Eli Lilly, Roche Diagnostics and Wave, has received travel support from Teva and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.